X4 PHARMACEUTICALS, INC Operating Leases, Rent Expense
X4 PHARMACEUTICALS, INC (XFOR) reported Operating Leases, Rent Expense of $1.30 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-11.
Discontinued › Expense Statement › Operating Expenses
us-gaap:LeaseAndRentalExpense · last filed 2019-03-11
- X4 PHARMACEUTICALS, INC operating leases, rent expense for the quarter ending 2018-12-31 was $300.00K, a 0.00% change year-over-year.
- X4 PHARMACEUTICALS, INC operating leases, rent expense for the quarter ending 2018-09-30 was $300.00K, a 0.00% change year-over-year.
- X4 PHARMACEUTICALS, INC operating leases, rent expense for the quarter ending 2018-06-30 was $300.00K, a 0.00% change year-over-year.
- X4 PHARMACEUTICALS, INC operating leases, rent expense for the quarter ending 2018-03-31 was $400.00K.
- X4 PHARMACEUTICALS, INC operating leases, rent expense for fiscal 2018 was $1.30M, a 8.33% increase from fiscal 2017.
- X4 PHARMACEUTICALS, INC operating leases, rent expense for fiscal 2017 was $1.20M, a 0.00% change from fiscal 2016.
- X4 PHARMACEUTICALS, INC operating leases, rent expense for fiscal 2016 was $1.20M.
| Period end | Operating Leases, Rent Expense 3 month | Operating Leases, Rent Expense 6 month | Operating Leases, Rent Expense 9 month | Operating Leases, Rent Expense 12 month |
|---|---|---|---|---|
| 2018-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-11 | $600.00K derived: sum of 2 quarters · filed 2019-03-11 | $900.00K derived: sum of 3 quarters · filed 2019-03-11 | $1.30M 10-K · filed 2019-03-11 |
| 2018-09-30 | $300.00K 10-Q · filed 2018-11-09 | $600.00K derived: sum of 2 quarters · filed 2018-11-09 | $1.00M 10-Q · filed 2018-11-09 | $1.30M derived: sum of 4 quarters · filed 2019-03-11 |
| 2018-06-30 | $300.00K 10-Q · filed 2018-08-13 | $600.00K 10-Q · filed 2018-08-13 | $1.00M derived: sum of 3 quarters · filed 2019-03-11 | $1.30M derived: sum of 4 quarters · filed 2019-03-11 |
| 2018-03-31 | $400.00K derived: 10-K 12 month − 3 quarters · filed 2019-03-11 | $700.00K derived: sum of 2 quarters · filed 2019-03-11 | $1.00M derived: sum of 3 quarters · filed 2019-03-11 | $1.30M derived: sum of 4 quarters · filed 2019-03-11 |
| 2017-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-11 | $600.00K derived: sum of 2 quarters · filed 2019-03-11 | $900.00K derived: sum of 3 quarters · filed 2019-03-11 | $1.20M 10-K · filed 2019-03-11 |
| 2017-09-30 | $300.00K 10-Q · filed 2018-11-09 | $600.00K derived: sum of 2 quarters · filed 2018-11-09 | $900.00K 10-Q · filed 2018-11-09 | |
| 2017-06-30 | $300.00K 10-Q · filed 2018-08-13 | $600.00K 10-Q · filed 2018-08-13 | ||
| 2016-12-31 | $1.20M 10-K · filed 2019-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |